ArticleDermatology reports2026
Oral isotretinoin for the treatment of dermatologic conditions other than acne: a case series.
Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatophyte infections, also known as tinea, along with viral warts, are common skin conditions that can be difficult to treat, especially when they recur or resist standard therapies. Isotretinoin, a medication traditionally used for acne, has recently shown promise as an adjuvant therapy for these conditions. This retrospective case-series study included 4 adult patients with persistent or recurrent tinea infections (tinea cruris and tinea corporis) or viral warts (genital and facial) who were treated with oral isotretinoin in addition to standard therapies. The patients' demographics, clinical presentations, treatment regimens, and responses were analyzed. All 4 patients showed significant clinical improvement after starting isotretinoin. Two patients with viral warts achieved complete clearance, and two patients with tinea infections experienced notable improvement. No severe side effects were reported. This case series suggests that isotretinoin may be a promising adjunctive therapy for patients with persistent or recurrent tinea infections and viral warts. However, further quantitative controlled studies are needed to confirm these findings and establish optimal treatment protocols. This study provides preliminary evidence for the potential benefit of using isotretinoin as an adjunctive therapy for recalcitrant tinea infections and viral warts. Further research is warranted to explore its efficacy and safety in larger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.